FDA label b17bfa50-3764-45fe-9531-c7af10a3db41

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
ca75d389-2c30-4cd4-bfc8-26f0e7cbb555
SPL ID
b17bfa50-3764-45fe-9531-c7af10a3db41
Version
5
Effective date
2015-09-15
Source export date
2026-10-12
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/befa34274042a52f589b22fe2add0b1c6f0a385c96447c28303de164bb144af5/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 02:37:05

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

WARNINGS AND PRECAUTIONS WARNINGS: Patients should be instructed to strictly adhere to the recommended dosage and administration guidelines set forth in this literature and on your prescription label. Accidental Exposure in Children: the potential exists for a small child or a pet to suffer adverse effects from chewing or ingesting a new or used Megrix biofrequency chip. It is important for patients to store and dispose of Megrix biofrequency chips out of the reach of children and pets. For external use only. Although the Megrix biofrequency chip contains low frequency waves, it has not been studied with a cardiac pacemaker or defibrillator. Consultation with the attending cardiologist is recommended for patients with implanted electrical devices. The Megrix biofrequency chip should be removed prior to any imaging procedures (e.g. CT scan, MRI, X-ray etc.). The Megrix biofrequency chip should not be used if there are mental or physical conditions that may preclude compliance with physician instructions. PRECAUTIONS: When traveling by air, do not wear the Megrix biofrequency chip when passing through passenger screening devices or the biofrequency chip could be damaged. Application to broken or inflamed skin, although not tested, may result in higher blood concentrations from increased absorption. Megrix is only recommended for use on intact skin. The contact of Megrix biofrequency chips with eyes, although not studied, should be avoided based on the findings of severe eye irritations with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline. PREGNANCY: The safety of Megrix biofrequency chip has not been established during pregnancy. ADVERSE REACTIONS: The most common adverse reactions are application site reactions, including dermatitis, itching or scaling. These tend to be dose-limiting and diminish with time. OVERDOSAGE: There have been no reports of over-dosage with Megrix biofrequency chip. Signs of overdosage could include vomiting, drowsiness, coma, respiratory depression, and seizures. In the case of an overdosage, discontinue the product immediately, treat the patient symptomatically, and institute supportive measures.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.